Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-12-29
2010-02-23
Whiteman, Brian (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
Reexamination Certificate
active
07667027
ABSTRACT:
Antisense-oligonucleotides or effective derivatives thereof hybridizing with an area of a gene coding for transforming growth factor-β (TGF-β) comprising the following nucleic acid sequences identified in the sequence listing under SEQ ID NO. 1-56 and 137 or comprising the following nucleic acid sequences identified in the sequence listing under SEQ ID NO. 57 to 136 each of the nucleic acids having a DNA- or RNA-type structure.
REFERENCES:
patent: 5221620 (1993-06-01), Purchio et al.
patent: 5464945 (1995-11-01), Reynolds et al.
patent: 5596072 (1997-01-01), Culpepper et al.
patent: 0293785 (1988-12-01), None
patent: 0433225 (1991-06-01), None
Hatzfeld et al.; “Release of Early Human Hematopoietic Progenitors from Quiescence by Antisense Transforming Growth Factor β1 or Rb Oligonucleotides”; Journal of Experimental Medicine, Oct. 1991; 3 pages; [XP000571050].
Slawomir et al.; “Reversal of Tumor-Induced Immunosuppression: A New Approach to Cancer Therapy”; Journal of Immunotherapy; Feb. 1997; p. 165-177.
Slawomir et al.; “Reversal of tumor-induced immunosuppression by TGF-β inhibitors”; Investigational New Drugs; vol. 21; p. 2-32; 2003.
Boedahn, et al., “Autocrine stimulation of malignant gliomas in vitro by TGF-β: A study with phosphorothioate antisense oligonucleotides,”Proceeding of the Annual Meeting of the American Association for Cancer Research, 34, 518 (1993), Abstract, ISSN: 0197-016X [XP-002137611 (3091)].
Maxwell et al., “Effect of the expression of transforming growth factor-β2 in primary human glioblastomas on immunosuppression and loss of immune surveillance,”J Neurosurg, 76, 799-804 (1992) [XP-000907113].
Chai et al., “Specific transforming growth factor-β subtypes regulate embryonic mouse Meckel's cartilage and tooth development,”Developmental Biology, 162, 85-103 (1994) [XP-000907143].
Tanaka et al., “Synthesis of oligoribonucleotides via the phosphite-triester approach on a polymer support,”Chem. Pharm. Bull., 34, 1426-1432 (1986) [XP-002058337].
Jachimczak, et al., “The effect of transforming growth factor-β2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma,”J. Neurosurg, 78, 944-951 (Jun. 1993) [XP-000886109].
Branch, Tibs, 23:45-50, Feb. 1998.
Ueki et al., Excessive production of transforming growth-factor . . . ; XP-002117560; Biochimica et Biophysica Acta, 1137 (1992) pp. 189-1960.
Martin et al., Complementary DNA for human glioblastoma-derived . . . ; The EMBO Journal, (1987), vol. 6, No. 12, pp. 3673-3677.
Bogdahn Ulrich
Brysch Wolfgang
Schlingensiepen Georg-Ferdinand
Schlingensiepen Karl-Hermann
Schlingensiepen Reimar
Biognostik Gesellschaft Fur Biomolekulare Diagnostik mbH
Jacobson & Holman PLLC
Whiteman Brian
LandOfFree
Antisense-oligonucleotides for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense-oligonucleotides for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense-oligonucleotides for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4181448